Director Mark Goldberg awarded 5,500 options at Intensity Therapeutics (INTS)
Rhea-AI Filing Summary
Intensity Therapeutics, Inc. director Mark A. Goldberg received a grant of stock options covering 5,500 shares of common stock. The options have an exercise price of $4.90 per share, expire on 2036-07-16, and are held directly. They will vest in four equal annual installments beginning on July 16, 2026, subject to his continued service.
Positive
- None.
Negative
- None.
Insider Trade Summary
1 transaction reported
Mixed
1 txn
Insider
GOLDBERG MARK A
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (right to buy Common Stock) F1 | 5,500 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Option (right to buy Common Stock) — 5,500 shares (Direct)
Footnotes (1)
- F1. This option will vest, subject to the individual's continued service with Intensity Therapeutics, Inc., in four, equal, annual installments, beginning on July 16, 2026.
Key Figures
Stock options granted: 5,500 options
Exercise price: $4.90 per share
Expiration date: 2036-07-16
+2 more
5 metrics
Stock options granted
5,500 options
Grant to director Mark A. Goldberg on 2026-07-16
Exercise price
$4.90 per share
Conversion or exercise price of the stock options
Expiration date
2036-07-16
Date on which the granted options expire
Vesting installments
4 equal annual installments
Vesting schedule beginning July 16, 2026, subject to continued service
Derivative holdings after grant
5,500 options
Total derivative securities held following the reported transaction
Key Terms
Stock Option (right to buy Common Stock), conversion or exercise price, derivative, vest
4 terms
Stock Option (right to buy Common Stock) financial
"security_title: "Stock Option (right to buy Common Stock)""
conversion or exercise price financial
""conversion_or_exercise_price": "4.9000" for the option grant"
derivative financial
""transaction_type": "derivative" for the reported option grant"
A derivative is a financial contract whose value depends on the price or performance of another asset or measure — for example a stock, index, interest rate, commodity, or currency. Investors use derivatives like insurance or leveraged bets to hedge risk, speculate, or gain exposure without owning the underlying asset; they can protect portfolios but also amplify losses and introduce counterparty and market risk.
vest financial
"This option will vest ... in four, equal, annual installments"
A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What insider transaction did INTENSITY THERAPEUTICS (INTS) report for Mark A. Goldberg?
Mark A. Goldberg reported receiving a grant of stock options for 5,500 shares of Intensity Therapeutics common stock. The Form 4 identifies this as a derivative transaction classified as a grant, award, or other acquisition of options held directly.
What is the exercise price and term of Mark A. Goldberg’s INTS stock options?
The granted options carry an exercise (conversion) price of $4.90 per share and an expiration date of 2036-07-16. These terms define the price Goldberg may pay per share and the final date on which the options can be exercised.
How do Mark A. Goldberg’s Intensity Therapeutics (INTS) options vest?
The options will vest in four equal annual installments beginning on July 16, 2026. Vesting is expressly conditioned on Goldberg’s continued service with Intensity Therapeutics, meaning unvested portions depend on ongoing service to the company.
How many INTS derivative securities does Mark A. Goldberg hold after this transaction?
After the reported grant, Mark A. Goldberg holds 5,500 stock options representing the right to buy 5,500 shares of Intensity Therapeutics common stock. The Form 4 shows these derivative securities as being held under direct ownership following the transaction.
Is Mark A. Goldberg’s INTS option grant reported as made under a Rule 10b5-1 plan?
The Form 4’s Rule 10b5-1 checkbox is not marked, so this option grant is not designated in the filing as being made pursuant to a Rule 10b5-1 trading plan. No separate trading-plan footnote is indicated for this transaction.